Literature DB >> 12121723

Gleason score predicts androgen independent progression after androgen deprivation therapy.

E A Benaim1, C M Pace, C G Roehrborn.   

Abstract

OBJECTIVE: The Gleason system is the most widely utilized histologic grading system for prostate cancer and a powerful predictor of cancer behavior. In this study, we evaluated the prognostic value of the Gleason grading system in predicting progression to androgen independent prostate cancer (AIPC).
METHODS: Records from 150 patients with advanced or metastatic prostate cancer treated with androgen deprivation therapy (ADT) were retrospectively reviewed. Androgen independent progression was defined as two consecutive elevations of serum prostate specific antigen (PSA) above the nadir value. Kaplan-Meier and the Cox proportional hazards methods were used to assess potential predictors of progression to AIPC.
RESULTS: Patients with low and moderate Gleason scores experienced significantly longer remissions compared to those with Gleason score of 8-10 (p=0.0006, Log-Rank test). The cumulative hazard of progressing to AIPC increased by almost 70% for each unit increase in total Gleason score.
CONCLUSION: In this patient cohort the Gleason score was the only independent predictor of progression to AIPC.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12121723     DOI: 10.1016/s0302-2838(02)00238-5

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  3 in total

1.  Gleason score and pretreatment prostate-specific antigen in survival among patients with stage D2 prostate cancer.

Authors:  William D Figg; Michael E Franks; David Venzon; Paul Duray; Michael C Cox; W Marston Linehan; W Van Bingham; James A Eastham; Eddie Reed; Oliver Sartor
Journal:  World J Urol       Date:  2004-12-08       Impact factor: 4.226

2.  Persistence of senescent prostate cancer cells following prolonged neoadjuvant androgen deprivation therapy.

Authors:  Michael L Blute; Nathan Damaschke; Jennifer Wagner; Bing Yang; Martin Gleave; Ladan Fazli; Fangfang Shi; E Jason Abel; Tracy M Downs; Wei Huang; David F Jarrard
Journal:  PLoS One       Date:  2017-02-24       Impact factor: 3.240

3.  Intermediate PSA half-life after neoadjuvant hormone therapy predicts reduced risk of castration-resistant prostate cancer development after radical prostatectomy.

Authors:  Yong Jin Kang; Won Sik Jang; Jong Kyou Kwon; Cheol Yong Yoon; Joo Yong Lee; Won Sik Ham; Young Deuk Choi
Journal:  BMC Cancer       Date:  2017-11-23       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.